Published in final edited form as:

Bioorg Med Chem. 2008 July 15; 16(14): 6682–6688. doi:10.1016/j.bmc.2008.05.073.

Synthesis and monoamine transporter binding properties of 2β-[3'-(substituted benzyl)isoxazol-5-yl]- and 2β-[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3β-(substituted phenyl) tropanes

Chunyang Jin, Hernán A. Navarro, Kevin Page, and F. Ivy Carroll*

Organic and Medicinal Chemistry, Research Triangle Institute, PO Box 12194, Research Triangle Park, NC 27709-2194, USA

Abstract

A series of 2β-[3'-(substituted benzyl)isoxazol-5-yl]- and 2β-[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3β-(substituted phenyl)tropanes were prepared and evaluated for affinities at dopamine, serotonin, and norepinephrine transporters using competitive radioligand binding assays. The 2β-[3'-(substituted benzyl)isoxazol-5-yl]-3β-(substituted phenyl)tropanes (**3a–h**) showed high binding affinities for the dopamine transporter (DAT). The IC₅₀ values ranged from 5.9 to 22 nM. On the other hand, the 2β-[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3β-(substituted phenyl)tropanes (**4a–h**), with IC₅₀ values ranging from 65 to 173 nM, were approximately 3- to 25-fold less potent than the corresponding 2β-[3'-(substituted benzyl)isoxazol-5-yl]tropanes. All tested compounds were selective for the DAT relative to the norepinephrine transporter (NET) and serotonin transporter (5-HTT). 3β-(4-Methylphenyl)-2β-[3'-(4-fluorobenzyl)isoxazol-5-yl]tropane (**3b**) with IC₅₀ of 5.9 nM at the DAT and K_is of 454 nM and 113 nM at the NET and 5-HTT, respectively, was the most potent and DAT selective analog. Molecular modeling study suggested that the rigid conformation of the isoxazole side chain in **4a–h** might play an important effect on their low DAT binding affinities.

Keywords

Monoamine transporters; 3-Phenyltropanes; Isoxazoles; Cocaine; Addiction

1. Introduction

Cocaine abuse continues to be a significant medical problem in the United States. An estimated 2 million Americans currently use cocaine (past-month) according to the National Survey on Drug Use and Health (NSDUH).¹ In addition to its direct effects, cocaine abuse has also contributed to the increase of the spread of Human Immunodeficiency Virus (HIV) infection and drug-resistant tuberculosis.² At present, no effective medication is in clinical use for the treatment of cocaine abuse. In the central nervous system (CNS), cocaine (**1a**, Fig. 1) binds to the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter

*Corresponding author: Dr. F. Ivy Carroll, Research Triangle Institute, Post Office Box 12194, Research Triangle Park, NC 27709-2194, Telephone: 919 541-6679, Fax: 919 541-8868, E-mail: fic@rti.org.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

(5-HTT), and inhibits presynaptic reuptake of the respective neurotransmitters. It also has effects on the cholinergic, muscarinic, and σ receptors and sodium channels.^{3,4} It is believed that the DAT is the key recognition site for cocaine, mediating the behavioural and reinforcing effects that contribute to its abuse liability.^{4–8} The dopamine hypothesis of cocaine addiction has received further support from molecular biological studies involving DAT knockout mice and Positron Emission Tomography (PET).^{9,10} Accordingly, the discovery and development of potent and selective DAT inhibitors represents one of the promising approaches in the treatment of cocaine abuse.

Many research groups have sought to develop the 3-phenyltropane class of DAT inhibitors, with 3 β -phenyltropane-2 β -carboxylic acid methyl ester (WIN 35,065-2, **1b**) as the lead compound.^{11–19} A large part of our structure-activity relationships (SAR) studies was directed towards modification of the 4'-chloro and 4'-methyl analogs **1c,d**.¹⁶ Over the last several years, we have synthesized a large number of 3-phenyltropane analogs and evaluated them for binding at monoamine transporters. We have shown that a variety of 2 β -esters, amides, and heterocyclic groups possessing either a 4'-chloro or 4'-methylphenyl group at the 3 β -position had high-affinity for the DAT, in some cases, with considerably reduced affinity at the NET and 5-HTT.¹⁶ One of the more interesting classes of compounds in the heterocyclic series is the 2 β -[3'-(substituted phenyl)isoxazol-5-yl]-3 β -(substituted phenyl)tropanes (**2a–h**).²⁰ The DAT selective inhibitor RTI-336 (**2e**) is currently in advanced preclinical development.^{21, 22} The present study was undertaken to further explore the effect of substituents on the isoxazole ring of the 3 β -phenyltropanes. In this paper, we describe the synthesis of several 2 β -[3'-(substituted benzyl)isoxazol-5-yl]-3 β -(substituted phenyl)tropanes (**3a–h**) and 2 β -[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3 β -(substituted phenyl)tropanes (**4a–h**), and report their monoamine transporter binding properties.

2. Chemistry

The synthesis of 2 β -[3'-(substituted benzyl)isoxazol-5-yl]-3 β -(substituted phenyl)tropanes (**3a–h**) and 2 β -[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3 β -(substituted phenyl)tropanes (**4a–h**) starting with anhydroecgonine methyl ester (**5**), is outlined in Scheme 1. Briefly, conjugate addition of **5** with the appropriate Grignard reagent at -45°C in ethyl ether followed by trifluoroacetic acid (TFA) yielded 3 β -aryltropanes **6a,b**.²³ Following our previously reported procedure,^{20,24} a solution of **6a** was added at 0°C to the oxime dilithium salt, generated from the oxime of 1-(4-fluorophenyl)propan-2-one with *n*-butyllithium in tetrahydrofuran (THF) at room temperature, and the reaction was warmed to room temperature. After 20 hours, the reaction mixture was added to a 1:1 mixture of 3N hydrochloric acid and THF, and was refluxed for 5 hours. Column chromatography purification of the crude product afforded 2 β -[3'-(4-fluorobenzyl)isoxazol-5-yl]-3 β -(4-chlorophenyl)tropane (**3a**) in 41% yield. Under these conditions, none of the desired 2 β -[3'-methyl-4'-(4-fluorophenyl)isoxazol-5-yl]-3 β -(4-chlorophenyl)tropane (**4a**) was obtained. Alternatively, treatment of the oxime of 1-(4-fluorophenyl)propan-2-one with *n*-butyllithium in THF at 70°C for 30 minutes followed by addition of **6a** and refluxing for 3 hours afforded the corresponding mixture of addition intermediates. Subsequent cyclization in refluxing 3N hydrochloric acid and THF furnished a mixture of **3a** and **4a**, which were obtained in 4% and 7% yield, respectively, after careful column chromatography. The low yields of **3a** and **4a** were due to the formation of multiple by-products under the reaction conditions. However, none of the by-products was formed in quantities justifying isolation and identification. The stereochemistry of **3a** and **4a** was determined by ^1H NMR spectral analysis, particularly with the aid of coupling constants of C(2)-H and C(3)-H. The vicinal couplings of $J_{2\text{eq},3\text{ax}} = 5.9\text{ Hz}$ and $J_{3\text{ax},4\text{ax}} = 13.0\text{ Hz}$ for **3a**, and $J_{2\text{eq},3\text{ax}} = 6.0\text{ Hz}$ and $J_{3\text{ax},4\text{ax}} = 12.9\text{ Hz}$ for **4a**, respectively, are in good agreement with stereochemical assignments. By employing the modified reaction conditions, 2 β -(substituted isoxazol)tropane analogs **3b–h** and **4b–h** were prepared in the range of 3–43% and 4–18%

yield, respectively. The yields obtained along with the analytical data of target compounds are given in Table 1.

3. Biology

The binding affinities for the target compounds at the DAT, NET, and 5-HTT were determined via competitive binding assays using the previously reported procedures.^{25,26} The final concentration of radioligands in the assays were 0.5 nM [³H]WIN35,428 for the DAT, 0.5 nM [³H]nisoxetine for the NET and 0.2 nM [³H]paroxetine for the 5-HTT. The results of the binding studies, along with binding data of cocaine, WIN 35,065-2²¹ and **2a-h**²⁰ for comparison are listed in Table 2. Since the DAT has two binding sites, IC₅₀ values are reported. The NET and 5-HTT have only one binding site, thus K_i values were calculated for inhibition of binding at these two transporters.

4. Results and Discussion

SAR studies from our laboratory as well as others have shown that a variety of functional groups and substituents are well tolerated at the C(2)-position of 3β-phenyltropanes without loss of high-affinity for the DAT.^{16,27–29} Results from some of the analogs suggest an electrostatic interaction between the 2β-substituent and the binding site, whereas results from other analogs are more consistent with a hydrophobic or steric interaction, which is important for the high binding potency at the DAT. A possible explanation for the wide range of substituents that can be accommodated at the C(2)-position is the existence of more than one binding mode. Although the DAT tolerates ligands having a broad variety of 2β-substituents with little change in the affinity of the ligand, the nature of the substituents has a profound effect on the monoamine transporter selectivity.¹⁶ To obtain analogs with increased metabolic stability, we have replaced the metabolically labile 2β-ester group of the 3β-phenyltropanes by stable bioisosteric heterocyclic groups, which led to several analogs with high-affinity and selectivity for the DAT.^{20,24,30,31} Computational analyses of the electrostatic (molecular electrostatic potential), hydrophobic (calculated log*P*), and steric (substituted volume) properties of these 2β-heterocyclic analogs strongly suggested electrostatic interactions predominately contributed to their DAT binding affinities.²⁴

We previously reported that 2β-[3'-(substituted phenyl)isoxazol-5-yl]-3β-(substituted phenyl) tropanes (**2a-h**) possessed high binding affinities (IC₅₀ = 1.57 to 13 nM) at the DAT with lower affinities at the NET and 5-HTT.²⁴ One of the most potent and selective compounds in the series, RTI-336 (**2e**), had an IC₅₀ of 4.09 nM at the DAT and K_is of 1030 nM and 522 nM at the NET and 5-HTT, respectively, and is currently in advanced preclinical development.^{21, 22} In the present study, we expanded the 2β-(substituted isoxazol)tropanes including 2β-[3'-(substituted benzyl)isoxazol]tropanes **3a-h** and 2β-[3'-methyl-4'-(substituted phenyl)isoxazol]tropanes **4a-h** to further explore the effect of the substituents on the isoxazole ring. All of the analogs **3a-h** exhibited high DAT binding affinities similar to the corresponding 2β-[3'-(substituted phenyl)isoxazol]tropanes **2a-h**. The IC₅₀ values ranged from 5.9 to 22 nM. On the other hand, the 2β-[3'-methyl-4'-(substituted phenyl)isoxazol]tropanes **4a-h**, with IC₅₀ values ranging from 65 to 173 nM, were approximately 8- to 60-fold less potent than **2a-h**, and 3- to 25-fold less potent than **3a-h**. The particular substituents (F, Cl, CH₃, OCH₃) on the phenyl group of the isoxazole moiety appeared to have only a subtle effect on the DAT affinities. No correlation was observed between the DAT binding affinities with the calculated log*P* (clog*P*) of the compounds. All tested compounds in this study were selective for the DAT relative to the NET and 5-HTT. However, none of the compounds was as selective as the corresponding 2β-[3'-(substituted phenyl)isoxazol]tropanes **2a-h**.

A molecular modelling study was performed to determine whether conformational differences between **3a–h** and **4a–h** account for the observed DAT binding properties. The minimum-energy conformations (Fig. 2) of **3a** and **4a** were generated using the MMFF94 force field in Spartan'06 (Wavefunction, Inc., Irvine, CA). There were no significant differences in the relative conformations of the tropane ring and the benzene ring attached at C(3)-position. However, significant difference in the relative conformations of the isoxazole ring attached at C(2)-position was revealed by the alignment of minimum-energy conformations shown in Figure 2. It is worthy to note that the isoxazole oxygen atom in **4a** is pointed in an almost opposite direction compared to that in **3a**. The two benzene rings in **4a** are proximal, and the resultant steric hindrance increases the rigidity of the isoxazole side chain and perhaps decreases the ability of the ligand to adopt a higher affinity conformation at the DAT.

In summary, a new series of 3 β -phenyltropanes with various 2 β -[3'-(substituted benzyl)isoxazol] and 2 β -[3'-methyl-4'-(substituted phenyl)isoxazol] substituents were synthesized and evaluated for their monoamine transporter binding affinities. The 2 β -[3'-(substituted benzyl)isoxazol]tropanes **3a–h** exhibited high affinities (IC_{50} = 5.9 to 22 nM) at the DAT, which is similar to that of the corresponding 2 β -[3'-(substituted phenyl)isoxazol]tropanes **2a–h**. On the other hand, the 2 β -[3'-methyl-4'-(substituted phenyl)isoxazol]tropanes **4a–h** were approximately 3- to 25-fold less potent than the corresponding **3a–h**. Molecular modelling studies suggested that the conformational properties of the isoxazole moiety of **3a–h** and **4a–h** might play an important effect on their DAT binding affinities.

5. Experimental

Melting points were determined using a MEL-TEMP II capillary melting point apparatus and are uncorrected. Nuclear magnetic resonance (1H NMR and ^{13}C NMR) spectra were obtained on a Bruker Avance DPX-300 MHz NMR spectrometer. Chemical shifts are reported in parts per million (ppm) with reference to internal solvent. Mass spectra (MS) were obtained by electron impact at 70 eV on a Hewlett Packard 5989A instrument. Elemental analyses were performed by Atlantic Microlab Inc., Atlanta, GA. Optical rotations were measured on an AutoPol III polarimeter, purchased from Rudolf Research. Analytical thin-layer chromatography (TLC) was carried out using EMD silica gel 60 F₂₅₄ TLC plates. TLC visualization was achieved with a UV lamp or in an iodine chamber. Flash column chromatography was done on a CombiFlash Companion system using Isco prepacked silica gel columns or using EM Science silica gel 60Å (230–400 mesh). Unless otherwise stated, reagent-grade chemicals were obtained from commercial sources and were used without further purification. All moisture- and air-sensitive reactions and reagent transfers were carried out under dry nitrogen. All compounds described herein were prepared from natural (–)-cocaine, and therefore, they all possess the same absolute configuration as (–)-cocaine.

5.1. 3 β -(4-Chlorophenyl)-2 β -[3'-(4-fluorobenzyl)isoxazol-5-yl]tropane (**3a**)

To a stirred solution of 1-(4-fluorophenyl)propan-2-one (5.00 g, 33.0 mmol) in EtOH (75 mL) at room temperature under nitrogen was added K_2CO_3 (12.4 g, 99.0 mmol) followed by hydroxylamine hydrochloride (4.17 g, 66.0 mmol). After stirring for 5 h, the reaction mixture was filtered through a plug of Celite and the filtrate was concentrated under reduced pressure. The resultant residue was dissolved in Et₂O (200 mL), washed with brine (3 $\times$ 100 mL), and dried (Na_2SO_4). Removal of the solvent under reduced pressure afforded 1-(4-fluorophenyl)propan-2-one oxime (5.40 g) as an oil, which was used in the next step without further purification.

To a stirred solution of 1-(4-fluorophenyl)propan-2-one oxime (1.84 g, 11.0 mmol) in anhydrous THF (20 mL) at 0 °C under nitrogen was added a solution of BuLi in hexanes (1.6 M, 13.7 mL, 22.0 mmol). The reaction mixture was warmed to room temperature and stirred

for 1 h. A solution of **6a**²³ (1.07 g, 3.66 mmol) in anhydrous THF (5 mL) was then added. After stirring at room temperature for 20 h, the reaction was quenched by addition of a 20% NH₄Cl aqueous solution (10 mL). The organic layer was separated and the aqueous layer was extracted with EtOAc (3 × 50 mL). The combined organic phases were washed with brine (3 × 50 mL), dried (Na₂SO₄), and concentrated under reduced pressure. The resultant residue was then dissolved in a 1:1 mixture of 3 N HCl aqueous solution and THF (20 mL), and refluxed for 5 h. After cooling to room temperature, the mixture was washed with Et₂O (3 × 10 mL). The aqueous layer was made basic with NaHCO₃ and extracted with EtOAc (3 × 50 mL). The combined EtOAc extracts were dried (Na₂SO₄) and concentrated under reduced pressure. Flash column chromatography of the crude product on silica gel (40 g Isco prepacked column) using 0 → 10% Et₂O in hexanes with 5% Et₃N afforded **3a** (610 mg, 41%) as an oil: ¹H NMR (CDCl₃) δ 7.12–6.90 (m, 6H), 6.88–6.78 (m, 2H), 6.11 (s, 1H), 3.89 (d, *J* = 15.6 Hz, 1H), 3.80 (d, *J* = 15.6 Hz, 1H), 3.32–3.12 (m, 4H), 2.30–2.02 (m, 6H), 1.81–1.52 (m, 3H); ¹H NMR (300 MHz; C₆D₆) δ 7.05 (d, *J* = 8.7 Hz, 2H), 6.80–6.72 (m, 4H), 6.58 (d, *J* = 8.7 Hz, 2H), 6.11 (s, 1H), 3.67 (d, *J* = 15.3 Hz, 1H), 3.53 (d, *J* = 15.3 Hz, 1H), 2.93 (dd, *J* = 5.9, 2.6 Hz, 1H), 2.88–2.80 (m, 2H), 2.74 (ddd, *J* = 13.0, 5.9, 5.6 Hz, 1H), 1.91 (ddd, *J* = 13.0, 12.9, 2.7 Hz, 1H), 1.86 (s, 3H), 1.80–1.60 (m, 2H), 1.30–1.13 (m, 3H); ¹³C NMR (CDCl₃) δ 173.2, 162.1, 161.8 (d, *J*_{C,F} = 243 Hz), 140.3, 133.6 (d, *J*_{C,F} = 3.2 Hz), 132.1, 130.2 (d, *J*_{C,F} = 7.9 Hz), 128.8, 128.2, 115.3 (d, *J*_{C,F} = 21.1 Hz), 103.6, 65.4, 61.6, 46.3, 42.0, 35.4, 34.9, 31.7, 26.4, 25.0; MS (EI) *m/z* 410 (M⁺). The free base was converted to the hydrochloride salt: mp 192 °C (dec); [α]_D²⁰ –47.7° (*c* 0.34, CH₃OH); Anal. Calcd for C₂₄H₂₅Cl₂FN₂O·H₂O: C, 61.94; H, 5.85; N, 6.02. Found: C, 61.95; H, 5.74; N, 5.97.

5.2. 3β-(4-Chlorophenyl)-2β-[3'-(4-fluorobenzyl)isoxazol-5-yl]tropane (**3a**) and 3β-(4-chlorophenyl)-2β-[3'-methyl-4'-(4-fluorophenyl)isoxazol-5-yl]tropane (**4a**)

To a stirred solution of 1-(4-fluorophenyl)propan-2-one oxime (1.84 g, 11.0 mmol) in anhydrous THF (20 mL) at 0 °C under nitrogen was added a solution of BuLi in hexanes (1.6 M, 13.7 mL, 22.0 mmol). The reaction mixture was warmed to room temperature over 30 min, and then heated to 70 °C for another 30 min. A solution of **6a** (1.07 g, 3.66 mmol) in anhydrous THF (5 mL) was added. The resultant mixture was refluxed for 3 h. After cooling to room temperature, the reaction was quenched by addition of a 20% NH₄Cl aqueous solution (10 mL). The organic layer was separated and the aqueous layer was extracted with EtOAc (3 × 50 mL). The combined organic phases were washed with brine (3 × 50 mL), dried (Na₂SO₄), and concentrated under reduced pressure. The residue was partitioned between Et₂O (100 mL) and 2 N HCl (50 mL). The aqueous layer was separated, made basic with NaHCO₃, and extracted with EtOAc (3 × 50 mL). The combined EtOAc extracts were washed with brine (3 × 30 mL), dried (Na₂SO₄), and concentrated under reduced pressure. The resultant residue was then dissolved in a 1:1 mixture of 3 N HCl aqueous solution and THF (10 mL), and refluxed for 5 h. After cooling to room temperature, the mixture was made basic with NaHCO₃ and extracted with EtOAc (3 × 50 mL). The combined EtOAc extracts were dried (Na₂SO₄) and concentrated under reduced pressure. Flash column chromatography of the crude product on silica gel (40 g Isco prepacked column) using 0 → 10% Et₂O in hexanes with 10% Et₃N afforded **3a** (55.0 mg, 4%) and **4a** (101 mg, 7%).

Compound 4a—oil; ¹H NMR (CDCl₃) δ 7.17–6.88 (m, 6H), 6.77–6.67 (m, 2H), 3.54–3.44 (m, 1H), 3.27–3.08 (m, 2H), 3.04 (dd, *J* = 6.0, 2.1 Hz, 1H), 2.65 (ddd, *J* = 12.9, 12.9, 2.7 Hz, 1H), 2.30–2.08 (m, 5H), 2.02 (s, 3H), 1.78–1.62 (m, 3H); ¹³C NMR (CDCl₃) δ 168.9, 164.1, 159.3 (d, *J*_{C,F} = 221 Hz), 140.8, 132.1, 131.4 (d, *J*_{C,F} = 8.0 Hz), 129.2, 128.3, 126.6 (d, *J*_{C,F} = 3.5 Hz), 117.6, 115.8 (d, *J*_{C,F} = 21.4 Hz), 66.3, 62.0, 45.6, 42.1, 36.4, 35.8, 26.9, 25.2, 10.5; MS (EI) *m/z* 410 (M⁺). The free base was converted to the hydrochloride salt: mp 231 °C (dec); [α]_D²⁰ +22.2° (*c* 0.79, CH₃OH); Anal. Calcd for C₂₄H₂₅Cl₂FN₂O·H₂O: C, 61.94; H, 5.85; N, 6.02. Found: C, 61.69; H, 5.85; N, 5.80.

5.3. 3β-(4-Methylphenyl)-2β-[3'-(4-fluorobenzyl)isoxazol-5-yl]tropane (3b) and 3β-(4-methylphenyl)-2β-[3'-methyl-4'-(4-fluorophenyl)isoxazol-5-yl]tropane (4b)

The procedure for **3a** and **4a** was followed using 1.00 g (3.66 mmol) of **6b**²³ and 1.84 g (11.0 mmol) of 1-(4-fluorophenyl)propan-2-one oxime to give 105 mg (7%) of **3b** and 250 mg (18%) of **4b**.

Compound 3b—oil; ¹H NMR (CDCl₃) δ 7.12–6.90 (m, 6H), 6.86–6.74 (m, 2H), 6.10 (s, 1H), 3.90 (d, *J* = 15.6 Hz, 1H), 3.80 (d, *J* = 15.6 Hz, 1H), 3.35–3.12 (m, 4H), 2.30–2.02 (m, 9H), 1.82–1.52 (m, 3H); ¹³C NMR (CDCl₃) δ 173.6, 161.9, 161.7 (d, *J*_{C,F} = 244 Hz), 138.6, 135.8, 133.8 (d, *J*_{C,F} = 3.2 Hz), 130.2 (d, *J*_{C,F} = 7.9 Hz), 128.8, 127.3, 115.3 (d, *J*_{C,F} = 21.1 Hz), 103.6, 65.5, 61.8, 46.5, 42.0, 35.5, 35.0, 31.7, 26.4, 25.1, 21.1; MS (EI) *m/z* 390 (M⁺). The free base was converted to the hydrochloride salt: mp 165 °C (dec); [α]_D²⁰ –66.6° (c 0.29, CH₃OH); Anal. Calcd for C₂₅H₂₈ClFN₂O·1.5H₂O: C, 66.14; H, 6.88; N, 6.17. Found: C, 65.74; H, 6.51; N, 6.07.

Compound 4b—oil; ¹H NMR (CDCl₃) δ 7.05–6.84 (m, 6H), 6.69–6.59 (m, 2H), 3.51–3.43 (m, 1H), 3.23–3.08 (m, 2H), 3.03 (dd, *J* = 6.0, 2.1 Hz, 1H), 2.65 (ddd, *J* = 12.6, 12.6, 2.4 Hz, 1H), 2.35–2.08 (m, 8H), 2.01 (s, 3H), 1.75–1.62 (m, 3H); ¹³C NMR (75 MHz; CDCl₃) δ 169.4, 164.0, 159.2 (d, *J*_{C,F} = 226 Hz), 139.1, 135.8, 131.5 (d, *J*_{C,F} = 8.0 Hz), 128.8, 127.8, 126.8 (d, *J*_{C,F} = 3.4 Hz), 117.4, 115.5 (d, *J*_{C,F} = 21.3 Hz), 66.3, 62.1, 45.7, 42.1, 36.6, 36.1, 26.8, 25.2, 21.1, 10.5; MS (EI) *m/z* 390 (M⁺). The free base was converted to the hydrochloride salt: mp 208 °C (dec); [α]_D²⁰ +18.0° (c 0.25, CH₃OH); Anal. Calcd for C₂₅H₂₈ClFN₂O·1.75H₂O: C, 65.49; H, 6.92; N, 6.11. Found: C, 65.24; H, 6.53; N, 6.03.

5.4. 3β-(4-Chlorophenyl)-2β-[3'-(4-chlorobenzyl)isoxazol-5-yl]tropane (3c) and 3β-(4-chlorophenyl)-2β-[3'-methyl-4'-(4-chlorophenyl)isoxazol-5-yl]tropane (4c)

The procedure for **3a** and **4a** was followed using 1.07 g (3.66 mmol) of **6a** and 2.02 g (11.0 mmol) of 1-(4-chlorophenyl)propan-2-one oxime to give 85.0 mg (5%) of **3c** and 180 mg (12%) of **4c**.

Compound 3c—oil; ¹H NMR (CDCl₃) δ 7.31–7.22 (m, 2H), 7.14–7.07 (m, 2H), 7.03 (d, *J* = 8.4 Hz, 2H), 6.84 (d, *J* = 8.4 Hz, 2H), 6.11 (s, 1H), 3.90 (d, *J* = 15.6 Hz, 1H), 3.81 (d, *J* = 15.6 Hz, 1H), 3.36–3.14 (m, 4H), 2.30–2.04 (m, 6H), 1.82–1.53 (m, 3H); ¹³C NMR (CDCl₃) δ 173.3, 161.8, 140.3, 136.5, 132.6, 132.2, 130.1, 128.9, 128.7, 128.3, 103.7, 65.5, 61.7, 46.4, 42.1, 35.5, 34.9, 31.9, 26.5, 25.1; MS (EI) *m/z* 426 (M⁺). The free base was converted to the hydrochloride salt: mp 192 °C (dec); [α]_D²⁰ –88.3° (c 0.31, CH₃OH); Anal. Calcd for C₂₄H₂₅Cl₃N₂O·0.75H₂O: C, 60.39; H, 5.60; N, 5.87. Found: C, 60.70; H, 5.85; N, 5.62.

Compound 4c—oil; ¹H NMR (CDCl₃) δ 7.35–7.27 (m, 2H), 7.14–7.05 (m, 2H), 6.91 (d, *J* = 8.7 Hz, 2H), 6.67 (d, *J* = 8.7 Hz, 2H), 3.54–3.42 (m, 1H), 3.22–3.08 (m, 2H), 3.04 (dd, *J* = 6.0, 2.1 Hz, 1H), 2.64 (ddd, *J* = 12.9, 12.9, 2.7 Hz, 1H), 2.30–2.06 (m, 5H), 2.03 (s, 3H), 1.77–1.63 (m, 3H); ¹³C NMR (CDCl₃) δ 169.0, 157.7, 140.7, 133.9, 132.2, 131.0, 129.2, 129.0, 128.3, 117.5, 66.3, 62.0, 45.7, 42.1, 36.4, 35.8, 26.8, 25.2, 10.5; MS (EI) *m/z* 426 (M⁺). The free base was converted to the hydrochloride salt: mp 248 °C (dec); [α]_D²⁰ +71.4° (c 0.37, CH₃OH); Anal. Calcd for C₂₄H₂₅Cl₃N₂O·0.25H₂O: C, 61.55; H, 5.49; N, 5.89. Found: C, 61.49; H, 5.75; N, 5.78.

5.5. 3β-(4-Methylphenyl)-2β-[3'-(4-chlorobenzyl)isoxazol-5-yl]tropane (3d) and 3β-(4-methylphenyl)-2β-[3'-methyl-4'-(4-chlorophenyl)isoxazol-5-yl]tropane (4d)

The procedure for **3a** and **4a** was followed using 1.00 g (3.66 mmol) of **6b** and 2.02 g (11.0 mmol) of 1-(4-chlorophenyl)propan-2-one oxime to give 40.0 mg (3%) of **3d** and 160 mg (11%) of **4d**.

Compound 3d—oil; ^1H NMR (CDCl_3) δ 7.31–7.20 (m, 2H), 7.10–6.77 (m, 6H), 6.10 (s, 1H), 3.91 (d, J = 15.6 Hz, 1H), 3.81 (d, J = 15.6 Hz, 1H), 3.40–3.17 (m, 4H), 2.40–2.03 (m, 9H), 1.88–1.57 (m, 3H); ^{13}C NMR (CDCl_3) δ 161.8, 138.6, 136.6, 136.1, 132.5, 131.1, 130.2, 129.0, 128.7, 127.4, 103.8, 65.6, 62.0, 46.5, 42.1, 35.5, 34.9, 31.9, 26.6, 25.1, 21.2; MS (EI) m/z 406 (M^+). The free base was converted to the hydrochloride salt: mp 180 °C (dec); $[\alpha]_{\text{D}}^{20}$ –75.4° (c 0.40, CH_3OH); Anal. Calcd for $\text{C}_{25}\text{H}_{28}\text{Cl}_2\text{N}_2\text{O} \cdot 0.5\text{H}_2\text{O}$: C, 66.37; H, 6.46; N, 6.19. Found: C, 66.38; H, 6.61; N, 5.87.

Compound 4d—oil; ^1H NMR (CDCl_3) δ 7.30–7.23 (m, 2H), 6.95 (d, J = 8.1 Hz, 2H), 6.86 (d, J = 8.1 Hz, 2H), 6.67–7.57 (m, 2H), 3.53–3.44 (m, 1H), 3.23–3.09 (m, 2H), 3.04 (dd, J = 6.0, 2.0 Hz, 1H), 2.66 (ddd, J = 12.9, 12.9, 2.7 Hz, 1H), 2.26 (s, 3H), 2.25 (s, 3H), 2.24–2.04 (m, 2H), 2.02 (s, 3H), 1.78–1.63 (m, 3H); ^{13}C NMR (CDCl_3) δ 169.4, 157.6, 139.0, 136.0, 133.7, 131.2, 129.4, 128.9, 128.8, 127.8, 117.4, 66.3, 62.2, 45.7, 42.1, 36.6, 36.0, 26.9, 25.2, 21.1, 10.6; MS (EI) m/z 406 (M^+). The free base was converted to the hydrochloride salt: mp 245 °C (dec); $[\alpha]_{\text{D}}^{20}$ +51.1° (c 0.33, CH_3OH); Anal. Calcd for $\text{C}_{25}\text{H}_{28}\text{Cl}_2\text{N}_2\text{O} \cdot 1.25\text{H}_2\text{O}$: C, 64.45; H, 6.60; N, 6.01. Found: C, 64.50; H, 6.42; N, 5.92.

5.6. 3β-(4-Chlorophenyl)-2β-[3'-(4-methylbenzyl)isoxazol-5-yl]tropane (3e) and 3β-(4-chlorophenyl)-2β-[3'-methyl-4'-(4-methylphenyl)isoxazol-5-yl]tropane (4e)

The procedure for **3a** and **4a** was followed using 1.07 g (3.66 mmol) of **6a** and 1.79 g (11.0 mmol) of 1-(4-methylphenyl)propan-2-one oxime to give 250 mg (17%) of **3e** and 130 mg (9%) of **4e**.

Compound 3e—oil; ^1H NMR (CDCl_3) δ 7.16–6.96 (m, 6H), 6.88–6.79 (m, 2H), 6.13 (s, 1H), 3.91 (d, J = 16.5 Hz, 1H), 3.80 (d, J = 16.5 Hz, 1H), 3.33–3.13 (m, 4H), 2.34 (s, 3H), 2.30–2.03 (m, 6H), 1.82–1.53 (m, 3H); ^{13}C NMR (CDCl_3) δ 172.8, 162.3, 140.3, 136.0, 134.8, 132.1, 129.2, 128.9, 128.5, 128.2, 103.8, 65.4, 61.6, 46.3, 41.9, 35.5, 34.9, 32.0, 26.4, 25.0, 21.1; MS (EI) m/z 406 (M^+). The free base was converted to the hydrochloride salt: mp 108 °C (dec); $[\alpha]_{\text{D}}^{20}$ –70.0° (c 0.37, CH_3OH); Anal. Calcd for $\text{C}_{25}\text{H}_{28}\text{Cl}_2\text{N}_2\text{O} \cdot 0.5\text{H}_2\text{O}$: C, 66.37; H, 6.46; N, 6.19. Found: C, 66.26; H, 6.64; N, 6.04.

Compound 4e—oil; ^1H NMR (CDCl_3) δ 7.20–7.03 (m, 4H), 6.93 (d, J = 8.4 Hz, 2H), 6.65 (d, J = 8.4 Hz, 2H), 3.52–3.44 (m, 1H), 3.27–2.96 (m, 3H), 2.67 (ddd, J = 12.0, 12.0, 2.1 Hz, 1H), 2.36 (s, 3H), 2.32 (s, 3H), 2.26–2.07 (m, 2H), 2.03 (s, 3H), 1.76–1.62 (m, 3H); ^{13}C NMR (CDCl_3) δ 168.5, 158.0, 140.8, 137.4, 132.0, 129.5, 129.4, 129.2, 128.2, 127.6, 118.3, 66.4, 62.0, 45.4, 42.1, 36.2, 35.8, 26.8, 25.1, 21.3, 10.6; MS (EI) m/z 406 (M^+). The free base was converted to the hydrochloride salt: mp 248 °C (dec); $[\alpha]_{\text{D}}^{20}$ +61.5° (c 0.35, CH_3OH); Anal. Calcd for $\text{C}_{25}\text{H}_{28}\text{Cl}_2\text{N}_2\text{O} \cdot 0.5\text{H}_2\text{O}$: C, 66.37; H, 6.46; N, 6.19. Found: C, 66.62; H, 6.42; N, 6.07.

5.7. 3β-(4-Methylphenyl)-2β-[3'-(4-methylbenzyl)isoxazol-5-yl]tropane (3f) and 3β-(4-methylphenyl)-2β-[3'-methyl-4'-(4-methylphenyl)isoxazol-5-yl]tropane (4f)

The procedure for **3a** and **4a** was followed using 1.00 g (3.66 mmol) of **6b** and 1.79 g (11.0 mmol) of 1-(4-methylphenyl)propan-2-one oxime to give 550 mg (39%) of **3f** and 105 mg (7%) of **4f**.

Compound 3f—oil; ^1H NMR (CDCl_3) δ 7.10 (d, J = 8.1 Hz, 2H), 7.01 (d, J = 8.1 Hz, 2H), 6.95 (d, J = 7.8 Hz, 2H), 6.81 (d, J = 7.8 Hz, 2H), 6.15 (s, 1H), 3.92 (d, J = 15.0 Hz, 1H), 3.81 (d, J = 15.0 Hz, 1H), 3.35–3.13 (m, 4H), 2.33 (s, 3H), 2.30–2.02 (m, 9H), 1.85–1.50 (m, 3H); ^{13}C NMR (CDCl_3) δ 173.1, 161.9, 138.1, 135.6, 135.4, 134.8, 128.9, 128.6, 128.4, 127.2, 103.4, 65.2, 61.5, 46.3, 41.8, 35.4, 34.8, 31.7, 26.2, 24.8, 20.9, 20.8; MS (EI) m/z 386 (M^+). The free base was converted to the hydrochloride salt: mp 193 °C (dec); $[\alpha]_D^{20}$ –61.9° (c 0.43, CH_3OH); Anal. Calcd for $\text{C}_{26}\text{H}_{31}\text{ClN}_2\text{O}\cdot 0.75\text{H}_2\text{O}$: C, 71.54; H, 7.50; N, 6.42. Found: C, 71.61; H, 7.37; N, 6.34.

Compound 4f—oil; ^1H NMR (CDCl_3) δ 7.11 (d, J = 7.8 Hz, 2H), 6.94 (d, J = 7.8 Hz, 2H), 6.89 (d, J = 8.1 Hz, 2H), 6.61 (d, J = 8.1 Hz, 2H), 3.50–3.41 (m, 1H), 3.22–3.08 (m, 3H), 2.68 (ddd, J = 12.3, 12.3, 2.1 Hz, 1H), 2.40 (s, 3H), 2.24 (s, 6H), 2.21–2.06 (m, 2H), 2.01 (s, 3H), 1.72–1.60 (m, 3H); ^{13}C NMR (CDCl_3) δ 169.1, 157.8, 139.2, 137.2, 135.7, 129.6, 129.2, 128.8, 127.9, 127.7, 118.1, 66.5, 62.1, 45.6, 42.1, 36.4, 36.1, 26.8, 25.2, 21.3, 21.1, 10.6; MS (EI) m/z 386 (M^+). The free base was converted to the hydrochloride salt: mp 249 °C (dec); $[\alpha]_D^{20}$ +44.7° (c 0.34, CH_3OH); Anal. Calcd for $\text{C}_{26}\text{H}_{31}\text{ClN}_2\text{O}\cdot 1.25\text{H}_2\text{O}$: C, 70.10; H, 7.58; N, 6.29. Found: C, 70.22; H, 7.36; N, 6.35.

5.8. 3 β -(4-Chlorophenyl)-2 β -[3'-(4-methoxybenzyl)isoxazol-5-yl]tropane (3g) and 3 β -(4-chlorophenyl)-2 β -[3'-methyl-4'-(4-methoxyphenyl)isoxazol-5-yl]tropane (4g)

The procedure for **3a** and **4a** was followed using 1.07 g (3.66 mmol) of **6a** and 1.97 g (11.0 mmol) of 1-(4-methoxyphenyl)propan-2-one oxime to give 510 mg (33%) of **3g** and 101 mg (7%) of **4g**.

Compound 3g—oil; ^1H NMR (CDCl_3) δ 7.14–6.99 (m, 4H), 6.90–6.80 (m, 4H), 6.10 (s, 1H), 3.89 (d, J = 15.6 Hz, 1H), 3.81 (s, 3H), 3.77 (d, J = 15.6 Hz, 1H), 3.34–3.13 (m, 4H), 2.30–2.05 (m, 6H), 1.83–1.56 (m, 3H); ^{13}C NMR (CDCl_3) δ 172.9, 162.6, 158.4, 140.4, 132.1, 130.0, 129.7, 128.9, 128.3, 114.0, 103.8, 65.4, 61.7, 55.4, 46.4, 42.0, 35.5, 35.0, 31.6, 26.5, 25.1; MS (EI) m/z 422 (M^+). The free base was converted to the hydrochloride salt: mp 178 °C (dec); $[\alpha]_D^{20}$ –62.4° (c 0.34, CH_3OH); Anal. Calcd for $\text{C}_{25}\text{H}_{28}\text{Cl}_2\text{N}_2\text{O}_2\cdot 0.75\text{H}_2\text{O}$: C, 63.49; H, 6.29; N, 5.92. Found: C, 63.20; H, 6.38; N, 5.78.

Compound 4g—white solid; mp 58.0–59.0 °C; ^1H NMR (CDCl_3) δ 7.14–7.08 (m, 2H), 6.95–6.80 (m, 4H), 6.72–6.63 (m, 2H), 3.82 (s, 3H), 3.52–3.42 (m, 1H), 3.24–3.06 (m, 3H), 2.66 (ddd, J = 12.3, 12.3, 2.4 Hz, 1H), 2.25 (s, 3H), 2.24–2.05 (m, 2H), 2.02 (s, 3H), 1.75–1.62 (m, 3H); ^{13}C NMR (CDCl_3) δ 168.6, 159.2, 158.1, 140.9, 132.0, 130.9, 129.2, 128.2, 122.9, 118.1, 114.2, 66.5, 62.0, 55.4, 45.5, 42.1, 36.3, 35.8, 26.9, 25.2, 10.6; MS (EI) m/z 422 (M^+). The free base was converted to the hydrochloride salt: mp 243 °C (dec); $[\alpha]_D^{20}$ +69.4° (c 0.39, CH_3OH); Anal. Calcd for $\text{C}_{25}\text{H}_{28}\text{Cl}_2\text{N}_2\text{O}_2\cdot 1.25\text{H}_2\text{O}$: C, 62.31; H, 6.38; N, 5.81. Found: C, 62.34; H, 6.42; N, 5.77.

5.9. 3 β -(4-Methylphenyl)-2 β -[3'-(4-methoxybenzyl)isoxazol-5-yl]tropane (3h) and 3 β -(4-methylphenyl)-2 β -[3'-methyl-4'-(4-methoxyphenyl)isoxazol-5-yl]tropane (4h)

The procedure for **3a** and **4a** was followed using 1.00 g (3.66 mmol) of **6b** and 1.97 g (11.0 mmol) of 1-(4-methoxyphenyl)propan-2-one oxime to give 631 mg (43%) **3h** and 52.0 mg (4%) of **4h**.

Compound 3h—oil; ^1H NMR (CDCl_3) δ 7.08–6.90 (m, 4H), 6.86–6.77 (m, 4H), 6.13 (s, 1H), 3.89 (d, J = 15.3 Hz, 1H), 3.80 (s, 3H), 3.79 (d, J = 15.3 Hz, 1H), 3.32–3.10 (m, 4H), 2.30–2.01 (m, 9H), 1.84–1.53 (m, 3H); ^{13}C NMR (CDCl_3) δ 173.2, 162.2, 158.2, 138.6, 135.6, 130.0, 129.6, 128.7, 127.3, 113.8, 103.5, 65.3, 61.7, 55.1, 46.4, 41.9, 35.5, 34.9, 31.4, 26.3, 24.9, 21.0; MS (EI) m/z 402 (M^+). The free base was converted to the hydrochloride salt: mp

168 °C (dec); $[\alpha]_D^{20}$ -68.7° (c 0.53, CH₃OH); Anal. Calcd for C₂₆H₃₁ClN₂O₂·1.5H₂O: C, 67.01; H, 7.35; N, 6.01. Found: C, 66.72; H, 7.33; N, 5.80.

Compound 4h—oil; ¹H NMR (CDCl₃) δ 7.00–6.76 (m, 6H), 6.66–6.55 (m, 2H), 3.82 (s, 3H), 3.50–3.40 (m, 1H), 3.20–3.02 (m, 3H), 2.67 (ddd, *J* = 12.3, 12.3, 2.1 Hz, 1H), 2.24 (s, 6H), 2.21–2.05 (m, 2H), 2.01 (s, 3H), 1.75–1.60 (m, 3H); ¹³C NMR (CDCl₃) δ 169.1, 159.1, 158.10, 139.3, 135.8, 131.0, 128.8, 127.8, 123.2, 117.9, 114.0, 66.5, 62.2, 55.4, 45.7, 42.2, 36.5, 36.2, 26.9, 25.2, 21.1, 10.6; MS (EI) *m/z* 402 (M⁺). The free base was converted to the hydrochloride salt: mp 238 °C (dec); $[\alpha]_D^{20}$ +50.7° (c 0.28, CH₃OH); Anal. Calcd for C₂₆H₃₁ClN₂O₂·1.25H₂O: C, 67.67; H, 7.32; N, 6.07. Found: C, 67.56; H, 7.35; N, 5.96.

Acknowledgements

This research was supported by the National Institute on Drug Abuse, Grant No. DA05477.

References

1. Substance Abuse and Mental Health Services Administration. 2003 National Survey on Drug Use and Health. Washington, DC: Department of Health and Human Services; 2003.
2. Hser YI, Chou CP, Hoffman V, Anglin MD. Sex. Transm. Dis 1999;26:82–86. [PubMed: 10029980]
3. Carroll FI, Lewin AH, Boja JW, Kuhar MJ. J. Med. Chem 1992;35:969–981. [PubMed: 1552510]
4. Kuhar MJ, Ritz MC, Boja JW. Trends Neurosci 1991;14:299–302. [PubMed: 1719677]
5. Bergman J, Madras BK, Johnson SE, Speelman RD. J. Pharmacol. Exp. Ther 1989;251:150–155. [PubMed: 2529365]
6. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. Science 1987;237:1219–1223. [PubMed: 2820058]
7. Wise RA, Leeb K, Pocock D, Newton P, Burnette B, Justice JB. Psychopharmacology (Berl.) 1995;120:10–20. [PubMed: 7480530]
8. Wilcox KM, Rowlett JK, Paul IA, Ordway GA, Woolverton WL. Psychopharmacology (Berl.) 2000;153:139–147. [PubMed: 11255924]
9. Volkow ND, Wang G-J, Fischman MW, Foltin RW, Fowler JS, Abumrad NN, Vitkun S, Logan J, Gatley SJ, Pappas N, Hitzemann R, Shea CE. Nature 1997;386:827–833. [PubMed: 9126740]
10. Rocha BA, Fumagalli F, Gainetdinov RR, Jones SR, Ator R, Giros B, Miller GW, Caron MG. Nat. Neurosci 1998;1:132–137. [PubMed: 10195128]
11. Clarke RL, Daum SJ, Gambino AJ, Aceto MD, Pearl J, Levitt M, Cumiskey WR, Bogado EF. J. Med. Chem 1973;16:1260–1267. [PubMed: 4747968]
12. Carroll, FI.; Lewin, AH.; Mascarella, SW. Neurotransmitter Transporters: Structure, Function, and Regulation. 2nd Edition. Reith, ME., editor. Totowa, NJ: Humana Press; 2001. p. 381–432.
13. Carroll FI. J. Med. Chem 2003;46:1775–1794. [PubMed: 12723940]
14. Dutta AK, Zhang S, Kolhatkar R, Reith ME. Eur. J. Pharmacol 2003;479:93–106. [PubMed: 14612141]
15. Singh S. Chem. Rev 2000;100:925–1024. [PubMed: 11749256]
16. Runyon SP, Carroll FI. Curr. Top. Med. Chem 2006;6:1825–1843. [PubMed: 17017960]
17. Carrera MR, Meijler MM, Janda KD. Bioorg. Med. Chem 2004;12:5019–5030. [PubMed: 15351386]
18. Newman AH, Kulkarni S. Med. Res. Rev 2002;22:429–464. [PubMed: 12210554]
19. Prisinzano T, Rice KC, Baumann MH, Rothman RB. Curr. Med. Chem.-Central Nervous System Agents 2004;4:47–59.
20. Carroll FI, Pawlusch N, Kuhar MJ, Pollard GT, Howard JL. J. Med. Chem 2004;47:296–302. [PubMed: 14711303]
21. Carroll FI, Howard JL, Howell LL, Fox BS, Kuhar MJ. AAPS J 2006;8:E196–E203. [PubMed: 16584128]
22. Carroll FI, Fox BS, Kuhar MJ, Howard JL, Pollard GT, Schenk S. Eur. J. Pharmacol 2006;553:149–156. [PubMed: 17067572]

23. Carroll FI, Gao Y, Rahman MA, Abraham P, Parham K, Lewin AH, Boja JW, Kuhar MJ. *J. Med. Chem* 1991;34:2719–2925. [PubMed: 1895292]
24. Kotian P, Mascarella SW, Abraham P, Lewin Anita H, Boja John W, Kuhar Michael J, Carroll FI. *J. Med. Chem* 1996;39:2753–2763. [PubMed: 8709106]
25. Boja JW, Rahman MA, Philip A, Lewin AH, Carroll FI, Kuhar MJ. *Mol. Pharmacol* 1991;39:339–345. [PubMed: 1826041]
26. Carroll FI, Gray JL, Abraham P, Kuzemko MA, Lewin AH, Boja JW, Kuhar MJ. *J. Med. Chem* 1993;36:2886–2890. [PubMed: 8411004]
27. Davies HML, Saikali E, Huby NJS, Gilliat VJ, Matasi JJ, Sexton T, Childers SR. *J. Med. Chem* 1994;37:1262–1268. [PubMed: 8176704]
28. Xu L, Kelkar SV, Lomenzo SA, Izenwasser S, Katz JL, Kline RH, Trudell ML. *J. Med. Chem* 1997;40:858–863. [PubMed: 9083474]
29. Kozikowski AP, Araldi GL, Prakash KR, Zhang M, Johnson KM. *J. Med. Chem* 1998;41:4973–4982. [PubMed: 9836615]
30. Kotian P, Abraham P, Lewin AH, Mascarella SW, Boja JW, Kuhar MJ, Carroll FI. *J. Med. Chem* 1995;38:3451–3453. [PubMed: 7658431]
31. Gong PK, Blough BE, Brieady LE, Huang X, Kuhar MJ, Navarro HA, Carroll FI. *J. Med. Chem* 2007;50:3686–3695. [PubMed: 17602602]

- 1a**, R = OCOC₆H₅
b, R = C₆H₅
c, R = 4ClC₆H₄
d, R = 4CH₃C₆H₄

- 2a**, X = Cl, Y = F
b, X = CH₃, Y = F
c, X = Cl, Y = Cl
d, X = CH₃, Y = Cl
e, X = Cl, Y = CH₃
f, X = CH₃, Y = CH₃
g, X = Cl, Y = OCH₃
h, X = CH₃, Y = OCH₃

- 3a**, X = Cl, Y = F
b, X = CH₃, Y = F
c, X = Cl, Y = Cl
d, X = CH₃, Y = Cl
e, X = Cl, Y = CH₃
f, X = CH₃, Y = CH₃
g, X = Cl, Y = OCH₃
h, X = CH₃, Y = OCH₃

- 4a**, X = Cl, Y = F
b, X = CH₃, Y = F
c, X = Cl, Y = Cl
d, X = CH₃, Y = Cl
e, X = Cl, Y = CH₃
f, X = CH₃, Y = CH₃
g, X = Cl, Y = OCH₃
h, X = CH₃, Y = OCH₃

Figure 1.
 Structures of cocaine (**1a**) and 3-phenyltropanes

Figure 2. Overlay (center; green: **3a** and purple: **4a**) of the calculated minimum-energy conformations of **3a** (left) and **4a** (right) (black: carbon; blue: nitrogen; red: oxygen; orange: chlorine; and green: fluorine)

Scheme 1.

Reagents and conditions: (a) Grignard reagent, -45°C , 2 h, then -78°C , TFA; (b) 1-(4-substituted phenyl)propan-2-one oxime, BuLi, THF, 0°C to 70°C ; (c) 3N HCl, THF, reflux.

Table 1
2β-Isloxazol-3β-(substituted phenyl)tropanes, yields, and analytical data

Compound ^a	X	Y	Yield (%)	[α] _D ²⁰ (g/100mL, CH ₃ OH)	mp (°C)	Molecular formula	Analysis

3a	Cl	F	4	-47.7° (0.34)	192 (dec)	C ₂₄ H ₂₅ Cl ₂ FN ₂ O·H ₂ O	C, H, N
3b	CH ₃	F	7	-66.6° (0.29)	165 (dec)	C ₂₅ H ₂₈ ClFN ₂ O·1.5H ₂ O	C, H, N
3c	Cl	Cl	5	-88.3° (0.31)	192 (dec)	C ₂₄ H ₂₅ Cl ₃ N ₂ O·0.75H ₂ O	C, H, N
3d	CH ₃	Cl	3	-75.4° (0.40)	180 (dec)	C ₂₅ H ₂₈ Cl ₂ N ₂ O·0.5H ₂ O	C, H, N
3e	Cl	CH ₃	17	-70.0° (0.37)	108 (dec)	C ₂₅ H ₂₈ Cl ₂ N ₂ O·0.5H ₂ O	C, H, N
3f	CH ₃	CH ₃	39	-61.9° (0.43)	193 (dec)	C ₂₆ H ₃₁ ClN ₂ O·0.75H ₂ O	C, H, N
3g	Cl	OCH ₃	33	-62.4° (0.34)	178 (dec)	C ₂₅ H ₂₈ Cl ₂ N ₂ O ₂ ·0.75H ₂ O	C, H, N
3h	CH ₃	OCH ₃	43	-68.7° (0.53)	168 (dec)	C ₂₆ H ₃₁ ClN ₂ O ₂ ·1.5H ₂ O	C, H, N
4a	Cl	F	7	+22.2° (0.79)	231 (dec)	C ₂₄ H ₂₅ Cl ₂ FN ₂ O·H ₂ O	C, H, N
4b	CH ₃	F	18	+18.0° (0.25)	208 (dec)	C ₂₅ H ₂₈ ClFN ₂ O·1.75H ₂ O	C, H, N
4c	Cl	Cl	12	+71.4° (0.37)	248 (dec)	C ₂₄ H ₂₅ Cl ₃ N ₂ O·0.25H ₂ O	C, H, N
4d	CH ₃	Cl	11	+51.1° (0.33)	245 (dec)	C ₂₅ H ₂₈ Cl ₂ N ₂ O·1.25H ₂ O	C, H, N
4e	Cl	CH ₃	9	+61.5° (0.35)	248 (dec)	C ₂₅ H ₂₈ Cl ₂ N ₂ O·0.5H ₂ O	C, H, N
4f	CH ₃	CH ₃	7	+44.7° (0.34)	249 (dec)	C ₂₆ H ₃₁ ClN ₂ O·1.25H ₂ O	C, H, N
4g	Cl	OCH ₃	7	+69.4° (0.39)	243 (dec)	C ₂₅ H ₂₈ Cl ₂ N ₂ O ₂ ·1.25H ₂ O	C, H, N
4h	CH ₃	OCH ₃	4	+50.7° (0.28)	238 (dec)	C ₂₆ H ₃₁ ClN ₂ O ₂ ·1.25H ₂ O	C, H, N

^a HCl salt used to characterize the compound.

Table 2
Monoamine transporter binding affinities of 2β-isoxazol-3β-(substituted phenyl)tropanes

Compound ^a	clog P	X	Y	DAT, IC ₅₀ ^b (nM) [³ H] WIN35,428	NET, K _i ^b (nM) [³ H] nisoxetine	5-HTT, K _i ^b (nM) [³ H] paroxetine
Cocaine ^c				89.1	1990	95
WIN35,065-2 ^c				23	556	182
2a ^d	4.48	Cl	F	1.86 ± 0.09	553 ± 65	660 ± 19
2b ^d	4.34	CH ₃	F	6.45 ± 1.6	552 ± 18	>2000
2c ^d	5.12	Cl	Cl	6.42 ± 0.46	>2000	>2000
2d ^d	4.98	CH ₃	Cl	8.74 ± 1.7	>2000	>2000
2e ^d	5.01	Cl	CH ₃	4.09 ± 0.44	1030 ± 24	522 ± 48
2f ^d	4.87	CH ₃	CH ₃	1.3 ± 2.1	>2000	>2000
2g ^d	4.36	Cl	OCH ₃	1.57 ± 0.1	454 ± 23	535 ± 16
2h ^d	4.23	CH ₃	OCH ₃	3.93 ± 0.49	455 ± 89	366 ± 2.9
3a	4.98	Cl	F	8.6 ± 3.0	435 ± 40	72 ± 8
3b	4.85	CH ₃	F	5.9 ± 1.5	454 ± 30	113 ± 8
3c	5.53	Cl	Cl	17.5 ± 1	677 ± 60	79 ± 36
3d	5.39	CH ₃	Cl	22.2 ± 5.5	840 ± 70	85 ± 12
3e	5.39	Cl	CH ₃	22.1 ± 2.8	1100 ± 140	42.9 ± 5
3f	5.26	CH ₃	CH ₃	6.9 ± 2.2	770 ± 40	89.7 ± 3.5
3g	4.85	Cl	OCH ₃	6.1 ± 1.4	347 ± 20	14.4 ± 1
3h	4.71	CH ₃	OCH ₃	9.6 ± 5	357 ± 50	41.1 ± 11
4a	5.09	Cl	F	111 ± 23	466 ± 40	908 ± 170
4b	4.96	CH ₃	F	76 ± 12	349 ± 70	>2000
4c	5.73	Cl	Cl	68.7 ± 4	788 ± 120	387 ± 130
4d	5.60	CH ₃	Cl	65.7 ± 22	519 ± 20	864 ± 250
4e	5.62	Cl	CH ₃	135 ± 34	>2000	297 ± 20
4f	5.49	CH ₃	CH ₃	173 ± 40	>2000	1000 ± 100
4g	4.98	Cl	OCH ₃	81.6 ± 22	>2000	1800 ± 300
4h	4.84	CH ₃	OCH ₃	119 ± 16	1300 ± 100	>2000

^a All compounds were tested as the HCl salt.

^b All values are means ± standard error of three or four experiments performed in duplicate.

^c Data taken from Ref. 21.

^d Data taken from Ref. 20.